Drug Profile
Prostate cancer vaccine - Jenner Biotherapies
Alternative Names: JBT 1001; OncoVax-PrLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Jenner Biotherapies (CEASED)
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 24 Aug 2005 No development reported - Phase-II for Prostate cancer in USA (Injection)
- 22 Aug 2000 A interim analysis of a phase II trial has been added to the Cancer therapeutic trials section
- 04 Mar 1999 Jenner Biotherapies has been awarded a US patent covering the use of prostate-specific antigen in prostate cancer vaccines